Terms: = Ovarian cancer AND WFDC2, EDDM4, HE4, WAP5, dJ461P17.6 AND Clinical Outcome
5 results:
1. The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers.
Carvalho VP; Grassi ML; Palma CS; Carrara HHA; Faça VM; Candido Dos Reis FJ; Poersch A
Transl Res; 2019 Apr; 206():71-90. PubMed ID: 30529050
[TBL] [Abstract] [Full Text] [Related]
2. Serum he4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
[TBL] [Abstract] [Full Text] [Related]
3. Preoperative he4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.
Braicu EI; Fotopoulou C; Van Gorp T; Richter R; Chekerov R; Hall C; Butz H; Castillo-Tong DC; Mahner S; Zeillinger R; Concin N; Vergote I; Sehouli J
Gynecol Oncol; 2013 Feb; 128(2):245-51. PubMed ID: 23178313
[TBL] [Abstract] [Full Text] [Related]
4. Immunohistochemical localization of he4 in benign, borderline, and malignant lesions of the ovary.
Georgakopoulos P; Mehmood S; Akalin A; Shroyer KR
Int J Gynecol Pathol; 2012 Nov; 31(6):517-23. PubMed ID: 23018214
[TBL] [Abstract] [Full Text] [Related]
5. Development of a multimarker assay for early detection of ovarian cancer.
Yurkovetsky Z; Skates S; Lomakin A; Nolen B; Pulsipher T; Modugno F; Marks J; Godwin A; Gorelik E; Jacobs I; Menon U; Lu K; Badgwell D; Bast RC; Lokshin AE
J Clin Oncol; 2010 May; 28(13):2159-66. PubMed ID: 20368574
[TBL] [Abstract] [Full Text] [Related]
